Characterization of Patients with EGFR Mutation-Positive NSCLC Following Emergence of the Osimertinib Resistance Mutations, L718Q or G724S: A Multicenter Retrospective Observational Study in France

References

• Barlesi F, Mazieres J, Merlio JP, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016;387(10026):1415–1426. doi:10.1016/S0140-6736(16)00004-0
   PubMed Web of Science ®Google Scholar
• Shah R, Lester JF. Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non-small-cell lung cancer: a clash of the generations. Clin Lung Cancer. 2020;21(3):e216–e228. doi:10.1016/j.cllc.2019.12.003
   PubMed Web of Science ®Google Scholar
• Park K, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17(5):577–589. doi:10.1016/S1470-2045(16)30033-X
   PubMed Web of Science ®Google Scholar
• Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. New Engl J Med. 2018;378(2):113–125. doi:10.1056/NEJMoa1713137
   PubMed Web of Science ®Google Scholar
• Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, Phase 3 trial. Lancet Oncol. 2017;18(11):1454–1466. doi:10.1016/S1470-2045(17)30608-3
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. New Engl J Med. 2020;382(1):41–50. doi:10.1056/NEJMoa1913662
   PubMed Web of Science ®Google Scholar
• Zeng Y, Yu D, Tian W, Wu F. Resistance mechanisms to osimertinib and emerging therapeutic strategies in non-small cell lung cancer. Curr Opinion Oncol. 2022;34(1):54–65. doi:10.1097/CCO.0000000000000805
   PubMed Web of Science ®Google Scholar
• Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169–181. doi:10.1038/nrc2088
   PubMed Web of Science ®Google Scholar
• Popat S, Hsia TC, Hung JY, et al. Tyrosine kinase inhibitor activity in patients with NSCLC harboring uncommon EGFR mutations: a retrospective international cohort study (UpSwinG). Oncologist. 2022;27(4):255–265. doi:10.1093/oncolo/oyac022
   PubMed Web of Science ®Google Scholar
• Kohsaka S, Nagano M, Ueno T, et al. A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer. Sci, trans med. 2017;9(416):eaan6566. doi:10.1126/scitranslmed.aan6566
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy. Cancer Sci. 2016;107(9):1179–1186. doi:10.1111/cas.12996
   PubMed Web of Science ®Google Scholar
• Robichaux JP, Le X, Vijayan RSK, et al. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature. 2021;597(7878):732–737. doi:10.1038/s41586-021-03898-1
   PubMed Web of Science ®Google Scholar
• Schmid S, Li JJN, Leighl NB. Mechanisms of osimertinib resistance and emerging treatment options. Lung Cancer. 2020;147:123–129. doi:10.1016/j.lungcan.2020.07.014
   PubMed Web of Science ®Google Scholar
• Piper-Vallillo AJ, Sequist LV, Piotrowska Z. Emerging treatment paradigms for EGFR-mutant lung cancers progressing on osimertinib: a review. J Clin Oncol. 2020;38(25):2926–2936. doi:10.1200/JCO.19.03123
   Web of Science ®Google Scholar
• Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br. J. Cancer. 2019;121(9):725–737. doi:10.1038/s41416-019-0573-8
   PubMed Web of Science ®Google Scholar
• Chmielecki J, Gray JE, Cheng Y, et al. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nat Commun. 2023;14(1):1070. doi:10.1038/s41467-023-35961-y
   PubMed Web of Science ®Google Scholar
• Brown BP, Zhang YK, Westover D, et al. On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele-specific manner dependent on the original EGFR-activating mutation. Clin Cancer Res. 2019;25(11):3341–3351. doi:10.1158/1078-0432.CCR-18-3829
   PubMed Web of Science ®Google Scholar
• Yang Z, Yang N, Ou Q, et al. Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients. Clin Cancer Res. 2018;24(13):3097–3107. doi:10.1158/1078-0432.CCR-17-2310
   PubMed Web of Science ®Google Scholar
• Fassunke J, Müller F, Keul M, et al. Overcoming EGFR(G724S)-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. Nat Commun. 2018;9(1):4655. doi:10.1038/s41467-018-07078-0
   PubMed Web of Science ®Google Scholar
• Gomatou G, Syrigos N, Kotteas E. Osimertinib resistance: molecular mechanisms and emerging treatment options. Cancers. 2023;15(3):841. doi:10.3390/cancers15030841
   PubMed Web of Science ®Google Scholar
• Yang JC, Schuler M, Popat S, et al. Afatinib for the treatment of non-small cell lung cancer harboring uncommon EGFR mutations: an updated database of 1023 cases brief report. Front Oncol. 2022;12:834704. doi:10.3389/fonc.2022.834704
   PubMed Web of Science ®Google Scholar
• Li M, Qin J, Xie F, Gong L, Han N, Lu H. L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment. Discover Oncol. 2022;13(1):72. doi:10.1007/s12672-022-00537-7
   PubMedGoogle Scholar
• Wei Y, Jiang B, Liu S, et al. Afatinib as a potential therapeutic option for patients with NSCLC with EGFR G724S. JTO Clin Res Rep. 2021;2(7):100193. doi:10.1016/j.jtocrr.2021.100193
   PubMedGoogle Scholar
• Minari R, Leonetti A, Gnetti L, et al. Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib. Anti-Cancer Drugs. 2021;32(7):758–762. doi:10.1097/CAD.0000000000001064
   PubMed Web of Science ®Google Scholar
• Fang W, Huang Y, Gan J, Zheng Q, Zhang L. Emergence of EGFR G724S after progression on osimertinib responded to Afatinib monotherapy. J Thoracic Oncol. 2020;15(3):e36–e37. doi:10.1016/j.jtho.2019.09.198
   PubMed Web of Science ®Google Scholar
• Cortiula F, Pelizzari G, Corvaja C, De Maglio G, Fasola G. Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to Afatinib monotherapy after multiple lines of target therapies. Anti-Cancer Drugs. 2022;33(9):960–962. doi:10.1097/CAD.0000000000001321
   PubMed Web of Science ®Google Scholar
• Peled N, Roisman LC, Miron B, et al. Subclonal therapy by two EGFR TKIs guided by sequential plasma cell-free DNA in EGFR-mutated lung cancer. J Thoracic Oncol. 2017;12(7):e81–e84. doi:10.1016/j.jtho.2017.02.023
   PubMedGoogle Scholar
• He SY, Lin QF, Chen J, Yu GP, Zhang JL, Shen D. Efficacy of Afatinib in a patient with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: a case report. World J Clin Cases. 2021;9(6):1329–1335. doi:10.12998/wjcc.v9.i6.1329
   PubMed Web of Science ®Google Scholar
• Liu J, Jin B, Su H, Qu X, Liu Y. Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report. BMC Cancer. 2019;19(1):702. doi:10.1186/s12885-019-5915-7
   PubMedGoogle Scholar
• Yang X, Huang C, Chen R, Zhao J. Resolving resistance to osimertinib therapy with Afatinib in an NSCLC patient with EGFR L718Q mutation. Clin Lung Cancer. 2020;21(4):e258–e260. doi:10.1016/j.cllc.2019.12.002
   PubMed Web of Science ®Google Scholar
• Mu Y, Hao X, Yang K, et al. Clinical modality of resistance and subsequent management of patients with advanced non-small cell lung cancer failing treatment with osimertinib. Target Oncol. 2019;14(3):335–342. doi:10.1007/s11523-019-00644-6
   PubMed Web of Science ®Google Scholar